DK2763694T3 - Fremstilling af et cystein-rigt protein - Google Patents
Fremstilling af et cystein-rigt protein Download PDFInfo
- Publication number
- DK2763694T3 DK2763694T3 DK12784427.2T DK12784427T DK2763694T3 DK 2763694 T3 DK2763694 T3 DK 2763694T3 DK 12784427 T DK12784427 T DK 12784427T DK 2763694 T3 DK2763694 T3 DK 2763694T3
- Authority
- DK
- Denmark
- Prior art keywords
- protein
- pfs45
- pfs48
- cysteine
- vaccine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4718—Cytokine-induced proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
- C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/055—Fusion polypeptide containing a localisation/targetting motif containing a signal for localisation to secretory granules (for exocytosis)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201100765 | 2011-10-04 | ||
PCT/DK2012/000108 WO2013050034A1 (en) | 2011-10-04 | 2012-10-03 | Production of a cysteine rich protein |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2763694T3 true DK2763694T3 (da) | 2018-04-16 |
Family
ID=47177694
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK12784427.2T DK2763694T3 (da) | 2011-10-04 | 2012-10-03 | Fremstilling af et cystein-rigt protein |
Country Status (4)
Country | Link |
---|---|
US (1) | US9422348B2 (da) |
EP (1) | EP2763694B1 (da) |
DK (1) | DK2763694T3 (da) |
WO (1) | WO2013050034A1 (da) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20150203547A1 (en) * | 2012-08-17 | 2015-07-23 | The United States of America, as represented by the Secretary, DHHS | Use of p47 from plasmodium falciparum (pfs47) or plasmodium vivax (pvs47) as a vaccine or drug screening targets for the inhibition of human malaria transmission |
CN109496237A (zh) * | 2016-06-10 | 2019-03-19 | 隆扎有限公司 | 用于稳定化蛋白质的方法 |
US20220194996A1 (en) | 2019-04-04 | 2022-06-23 | Statens Serum Institut | Multivalent Malaria Transmission-Blocking Vaccines |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4599231A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US4599230A (en) | 1984-03-09 | 1986-07-08 | Scripps Clinic And Research Foundation | Synthetic hepatitis B virus vaccine including both T cell and B cell determinants |
US4608251A (en) | 1984-11-09 | 1986-08-26 | Pitman-Moore, Inc. | LHRH analogues useful in stimulating anti-LHRH antibodies and vaccines containing such analogues |
US4601903A (en) | 1985-05-01 | 1986-07-22 | The United States Of America As Represented By The Department Of Health And Human Services | Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease |
DK200201741A (da) * | 2002-11-12 | 2003-09-16 | Statens Seruminstitut | Vaccine comprising chimeric malaria proteins derived from Plasmodium falciparum |
-
2012
- 2012-10-03 EP EP12784427.2A patent/EP2763694B1/en active Active
- 2012-10-03 WO PCT/DK2012/000108 patent/WO2013050034A1/en active Application Filing
- 2012-10-03 US US14/123,676 patent/US9422348B2/en active Active
- 2012-10-03 DK DK12784427.2T patent/DK2763694T3/da active
Also Published As
Publication number | Publication date |
---|---|
WO2013050034A1 (en) | 2013-04-11 |
EP2763694B1 (en) | 2018-01-03 |
US20140170182A1 (en) | 2014-06-19 |
EP2763694A1 (en) | 2014-08-13 |
US9422348B2 (en) | 2016-08-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7749507B2 (en) | Malaria vaccine | |
US20070003562A1 (en) | GLURP-MSP3 fusion protein, immunogenic compositions and malarial vaccines containing it | |
US20220409712A1 (en) | Biofusion proteins as anti-malaria vaccines | |
JP6461100B2 (ja) | アピコンプレクサ病原体に対する新規ワクチン | |
Rafati et al. | Leishmania major heat shock protein 70 (HSP70) is not protective in murine models of cutaneous leishmaniasis and stimulates strong humoral responses in cutaneous and visceral leishmaniasis patients | |
Taylor‐Robinson et al. | A role for cytokines in potentiation of malaria vaccines through immunological modulation of blood stage infection | |
DK2763694T3 (da) | Fremstilling af et cystein-rigt protein | |
Alaro et al. | Protective immune responses elicited by immunization with a chimeric blood-stage malaria vaccine persist but are not boosted by Plasmodium yoelii challenge infection | |
US20050095256A1 (en) | Recombinant process for preparing a complete malaria antigen gp190/MSP1 | |
Mehrizi et al. | Immune responses elicited by co‐immunization of Plasmodium vivax and P. falciparum MSP‐1 using prime‐boost immunization strategies | |
Singh et al. | Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate | |
US9346862B2 (en) | Canine babesiosis vaccine antigen | |
US5393523A (en) | Plasmodium falciparum vaccine comprising a recombinant histidine-rich protein-HRP-II | |
KR101598876B1 (ko) | 리슈마니아증 및 결핵에 대한 백신 개발을 위한 dna 키메라의 작제 | |
EP2409987A1 (en) | Ribosomal P protein complex from Plasmodium falciparum as antigen against malaria | |
JPWO2018159476A1 (ja) | 多価ワクチン | |
US20220194996A1 (en) | Multivalent Malaria Transmission-Blocking Vaccines | |
Seid | Rational vaccine development for malaria from genomic sequence information | |
Ravi et al. | Development of pilot scale production process and characterization of a recombinant multiepitope malarial vaccine candidate FALVAC-1A expressed in Escherichia coli |